JS Link, Inc.

KOSDAQ:A127120 Stock Report

Market Cap: ₩1.2t

JS Link Past Earnings Performance

Past criteria checks 0/6

JS Link's earnings have been declining at an average annual rate of -13.2%, while the Biotechs industry saw earnings growing at 16.1% annually. Revenues have been declining at an average rate of 2% per year.

Key information

-13.23%

Earnings growth rate

0.44%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate-2.04%
Return on equity-5.12%
Net Margin-23.26%
Last Earnings Update30 Jun 2026

Recent past performance updates

Recent updates

Analysis Article • Jan 22

JS Link, Inc. (KOSDAQ:127120) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected

JS Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 32% after a shaky period beforehand...
Analysis Article • Oct 10

JS Link, Inc.'s (KOSDAQ:127120) 26% Price Boost Is Out Of Tune With Revenues

Despite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...
Analysis Article • Oct 10

JS Link, Inc.'s (KOSDAQ:127120) Shares Climb 26% But Its Business Is Yet to Catch Up

Despite an already strong run, JS Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 26% in the...
Analysis Article • Aug 19

Optimistic Investors Push JS Link, Inc. (KOSDAQ:127120) Shares Up 34% But Growth Is Lacking

KOSDAQ:A127120 1 Year Share Price vs Fair Value Explore JS Link's Fair Values from the Community and select yours...
Analysis Article • Jul 05

JS Link, Inc.'s (KOSDAQ:127120) Popularity With Investors Is Under Threat From Overpricing

You may think that with a price-to-sales (or "P/S") ratio of 21.2x JS Link, Inc. ( KOSDAQ:127120 ) is a stock to avoid...
Analysis Article • Mar 26

There's Reason For Concern Over DNA Link, Inc.'s (KOSDAQ:127120) Massive 29% Price Jump

DNA Link, Inc. ( KOSDAQ:127120 ) shares have continued their recent momentum with a 29% gain in the last month alone...
Analysis Article • Dec 04

There's No Escaping DNA Link, Inc.'s (KOSDAQ:127120) Muted Revenues Despite A 27% Share Price Rise

Despite an already strong run, DNA Link, Inc. ( KOSDAQ:127120 ) shares have been powering on, with a gain of 27% in the...
Analysis Article • Jul 12

DNA Link, Inc. (KOSDAQ:127120) Shares Fly 27% But Investors Aren't Buying For Growth

DNA Link, Inc. ( KOSDAQ:127120 ) shares have had a really impressive month, gaining 27% after a shaky period...
Analysis Article • Mar 19

There Is A Reason DNA Link, Inc.'s (KOSDAQ:127120) Price Is Undemanding

You may think that with a price-to-sales (or "P/S") ratio of 2.6x DNA Link, Inc. ( KOSDAQ:127120 ) is definitely a...
Analysis Article • Apr 19

Is DNA Link (KOSDAQ:127120) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article • Feb 23

Introducing DNA Link (KOSDAQ:127120), A Stock That Climbed 61% In The Last Year

Some DNA Link, Inc. ( KOSDAQ:127120 ) shareholders are probably rather concerned to see the share price fall 66% over...

Revenue & Expenses Breakdown

How JS Link makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A127120 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2622,780-5,29819,89664
31 Mar 2620,307-15,76218,02769
31 Dec 2519,316-16,44517,36628
30 Sep 2516,139-12,41013,06312
30 Jun 2515,061-14,62612,27216
31 Mar 2514,273-15,15611,94619
31 Dec 2415,908-10,80210,75619
30 Sep 2419,042-11,3149,98220
30 Jun 2419,110-6,9418,75322
31 Mar 2421,046-4,2958,17019
31 Dec 2321,949-5,5968,57485
30 Sep 2318,947-6,4628,700214
30 Jun 2318,718-5,7858,49545
31 Mar 2317,427-5,6317,74166
31 Dec 2216,981-7,7827,141465
30 Sep 2219,141-7,0149,788518
30 Jun 2221,999-5,78610,207700
31 Mar 2223,186-7,52110,770792
31 Dec 2122,992-5,10010,603539
30 Sep 2119,730-9,6217,432635
30 Jun 2116,660-12,3756,862768
31 Mar 2115,903-13,1646,815660
31 Dec 2015,286-13,0676,798464
30 Sep 2015,654-14,56910,185255
30 Jun 2016,208-13,24710,376129
31 Mar 2015,333-12,61610,201354
31 Dec 1915,573-13,1189,955356
30 Sep 1914,397-5,3366,071360
30 Jun 1913,331-5,7136,071343
31 Mar 1914,300-4,9726,012120
31 Dec 1814,876-3,7536,010104
30 Sep 1814,860-2,5505,735411
30 Jun 1815,135-8635,274404
31 Mar 1814,819-234,656411
31 Dec 1714,4803384,076538
30 Sep 1714,888-2,9924,444-74
30 Jun 1714,620-5,7415,046599
31 Mar 1713,206-7,3245,016640
31 Dec 1611,484-9,8115,398585
30 Sep 1610,126-12,9385,5571,809
30 Jun 168,869-11,3414,5611,149
31 Mar 169,396-9,2834,587974
31 Dec 159,420-9,0544,1711,029
30 Sep 159,028-6,0184,20092

Quality Earnings: A127120 is currently unprofitable.

Growing Profit Margin: A127120 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A127120 is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.

Accelerating Growth: Unable to compare A127120's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A127120 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (23.9%).

Return on Equity

High ROE: A127120 has a negative Return on Equity (-5.12%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/22 09:02
End of Day Share Price 2026/09/22 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

JS Link, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Al Eum LeeiM Securities
Sung Hwan ChoiKyobo Securities Co., Ltd
Kidal BaeShinhan Investment Corp.